• KOL
    • KOLs Community
    • Prostate
    • Prostate Cancer
    • Arul M Chinnaiyan
    • Arul M Chinnaiyan

      Arul M Chinnaiyan

      Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA | Department of Pathology, University of Michigan, Ann Arbor, MI, USA | Howard Hughes Medical Institute, ...



      KOL Resume for Arul M Chinnaiyan


      Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA

      Michigan Center for Translational Pathology and Department of Pathology, The University of Michigan Medical School, Ann Arbor, United States of America

      Department of Pathology, UMMS.


      Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109;

      Department of Pediatric Oncology, Dana-Farber Boston Children’s Cancer and Blood Disorders Center, ; Boston, USA



      Arul M Chinnaiyan: Influence Statistics

      Sample of concepts for which Arul M Chinnaiyan is among the top experts in the world.
      Concept World rank
      bet proteins crpc #1
      cell migration cbd #1
      protease domain ced4 #1
      recurrent etv1 amplification #1
      networks majority #1
      hbp crpc #1
      tmprss2erg gene fusions #1
      twopass alignment #1
      disrupt resistance #1
      azgp1 autoantibody #1
      amacr expression specimens #1
      immunohistochemistry amacr #1
      prostate cancer parp1 #1
      treatment resistance mechanism #1
      proteins l23 #1
      idc gleason pattern #1
      edel tmprss2 #1
      tmprss2erg vcap cells #1
      cyp2c19 mioncoseq patients #1
      putative cell origin #1
      apc transrectal biopsy #1
      src2 nude mice #1
      tslp bmdc #1
      fusion prostatic neoplasms #1
      chimeric transcript discovery #1
      prognostic g4 #1
      tissue pca3 #1
      combination urine pca3 #1
      foci evaluation #1
      chemical beti #1
      adults translocation rcc #1
      solid tumors identification #1
      slit2 prostate cancer #1
      dominant heterozygote histones #1
      prostate tumorigenesis vivo #1
      fh ihc sdhb #1
      practical genes #1
      lncrna pcat29 #1
      archived ctcs patients #1
      erg fusion transcript #1
      utility polya #1
      ezhipwt #1
      cutaneous cis scc #1
      lncrnas linc00402 #1
      pcptrc mps #1
      southern catalytic lymphocytic #1
      wildtype erg #1
      capacity erlotinib #1
      fusion predictive #1
      evade therapy #1


      Prominent publications by Arul M Chinnaiyan

      KOL-Index: 21263

      BACKGROUND: TMPRSS2:ERG (T2:ERG) and prostate cancer antigen 3 (PCA3) are the most advanced urine-based prostate cancer (PCa) early detection biomarkers.

      OBJECTIVE: Validate logistic regression models, termed Mi-Prostate Score (MiPS), that incorporate serum prostate-specific antigen (PSA; or the multivariate Prostate Cancer Prevention Trial risk calculator version 1.0 [PCPTrc]) and urine T2:ERG and PCA3 scores for predicting PCa and high-grade PCa on biopsy.


      Known for Cancer Risk | Pca Psa | Urine Tmprss2 | Miprostate Score | Curve Biomarkers
      KOL-Index: 20881

      The link between ERG rearrangement and PTEN (phosphatase and tensin homolog deleted on chromosome 10) deletion is unclear in prostate cancer progression. Using fluorescence in situ hybridization, we systematically validated the frequency and distribution of ERG and PTEN aberrations in a cohort of 73 benign prostate tissues, 59 high-grade prostatic intraepithelial neoplasia (HGPIN) foci, 281 localized prostate cancer and 47 androgen-independent metastatic prostate cancer patients. ...

      Known for Pten Deletion | Erg Rearrangement | Situ Hybridization | Prostate Cancer Progression | Tensin Homolog
      KOL-Index: 20441

      OBJECTIVES: We sought to develop a clinical algorithm combining serum PSA with detection of TMPRSS2:ERG fusion and PCA3 in urine collected after digital rectal exam (post-DRE urine) to predict prostate cancer on subsequent biopsy.

      MATERIALS AND METHODS: Post-DRE urine was collected in 48 consecutive patients before prostate biopsy at 2 centers; quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to detect PCA3 and TMPRSS2:ERG fusion transcript expression. ...

      Known for Serum Psa | Prostate Cancer | Tmprss2 Erg | Neoplasm Biomarkers | Urinary Detection
      KOL-Index: 17882

      CONTEXT: Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens.

      OBJECTIVES: To determine the expression and clinical utility of alpha-methylacyl coenzyme A racemase (AMACR), a gene identified as being overexpressed in prostate cancer by global profiling strategies.

      DESIGN: Four gene expression data sets from ...

      Known for Prostate Cancer | Tissue Biomarker | Messenger Racemases | Specificity Amacr | Tumor Biopsy
      KOL-Index: 17726

      Human enhancer of zeste 2 (EZH2) protein belongs to the multiprotein polycomb repressive complex 2, which also includes suppressor of zeste 12 (SUZ12) and embryonic ectoderm development (EED). The polycomb repressive complex 2 complex possesses histone methyltransferase activity mediated by the Su(var)3-9, enhancer of zeste, and trithorax domain of EZH2, which methylates histone H3 on lysine (K)-27 (H3K27). In the present studies, we determined that treatment with the hydroxamate histone ...

      Known for Histone Deacetylase | 2 Protein | Acute Leukemia | Polycomb Repressive | Aml Cells
      KOL-Index: 17384

      Renal cell carcinomas with MITF aberrations demonstrate a wide morphologic spectrum, highlighting the need to consider these entities within the differential diagnosis of renal tumors encountered in clinical practice. Herein, we describe our experience with application of clinical fluorescence in situ hybridization (FISH) assays for detection of TFE3 and TFEB gene aberrations from 85 consecutive renal cell carcinoma cases submitted to our genitourinary FISH service. Results from 170 FISH ...

      Known for Renal Cell | Tumor Carcinoma | Situ Hybridization | Tfeb Fish | Differential Diagnosis
      KOL-Index: 16430

      Prostate cancer is a common and clinically heterogeneous disease with marked variability in progression. The recent identification of gene fusions of the 5'-untranslated region of TMPRSS2 (21q22.3) with the ETS transcription factor family members, either ERG (21q22.2), ETV1 (7p21.2), or ETV4 (17q21), suggests a mechanism for overexpression of the ETS genes in the majority of prostate cancers. In the current study using fluorescence in situ hybridization (FISH), we identified the ...

      Known for Erg Tmprss2 | Prostate Cancer | 5untranslated Region | Tumor Gene | Single Nucleotide
      KOL-Index: 16175

      We recently reported the identification of recurrent gene fusions in the majority of prostate cancers involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS family members ERG, ETV1, and ETV4. Here we report the noninvasive detection of these gene fusions in the urine of patients with clinically localized prostate cancer. By quantitative polymerase chain reaction, we assessed the expression of ERG and TMPRSS2:ERG transcripts in urine samples obtained ...

      Known for Prostate Cancer | Fusion Transcripts | Noninvasive Detection | Urine Patients | Tmprss2 Erg
      KOL-Index: 15403

      The Hippo pathway plays a key role in organ size control by regulating cell proliferation and apoptosis in Drosophila. Although recent genetic studies have shown that the Hippo pathway is regulated by the NF2 and Fat tumor suppressors, the physiological regulations of this pathway are unknown. Here we show that in mammalian cells, the transcription coactivator YAP (Yes-associated protein), is inhibited by cell density via the Hippo pathway. Phosphorylation by the Lats tumor suppressor ...

      Known for Hippo Pathway | Contact Inhibition | Yap Oncoprotein | Growth Control | Drosophila Proteins
      KOL-Index: 15252

      Breast cancer presents as either estrogen receptor alpha (ERalpha) positive or negative, with ERalpha+ tumors responding to antiestrogen therapy and having a better prognosis. By themselves, mRNA expression signatures of estrogen regulation in ERalpha+ breast cancer cells do not account for the vast molecular differences observed between ERalpha+ and ERalpha- cancers. In ERalpha- tumors, overexpression of epidermal growth factor receptor (EGFR) or c-erbB-2, leading to increased growth ...

      Known for Estrogen Receptor | Breast Cancer | Protein Kinase | Eralpha Expression | Cell Lines
      KOL-Index: 15005

      PURPOSE: Fusion of the TMPRSS2 prostate-specific gene with the ERG transcription factor is a putatively oncogenic gene rearrangement that is commonly found in prostate cancer tissue from men undergoing prostatectomy. However, the prevalence of the fusion was less common in samples of transurethral resection of the prostate from a Swedish cohort of patients with incidental prostate cancer followed by watchful waiting, raising the question as to whether the high prevalence in prostatectomy ...

      Known for Erg Fusion | Prostate Cancer | United States | Situ Hybridization | Gene Rearrangement
      KOL-Index: 14839

      Novel recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS family members ERG, ETV1, or ETV4 have been recently identified as a common molecular event in prostate cancer development. We comprehensively analyzed the frequency and risk of disease progression for the TMPRSS2 and ETS family genes rearrangements in a cohort of 96 American men surgically treated for clinically localized prostate cancer. Using three break apart (TMPRSS2, ERG, ETV4) and one fusion ...

      Known for Tmprss2 Erg | Prostate Cancer | Etv1 Etv4 | Gene Aberrations | Clinically Localized
      KOL-Index: 14778

      Identification of new molecular markers has led to the molecular classification of prostate cancer based on driving genetic lesions. The translation of these discoveries for clinical use necessitates the development of simple, reliable and rapid detection systems to screen patients for specific molecular aberrations. We developed two dual-color immunohistochemistry-based assays for the simultaneous assessment of ERG-PTEN and ERG-SPINK1 in prostate cancer. A total of 232 cases from 184 ...

      Known for Erg Spink1 | Situ Hybridization | Cases Pten | Prostate Cancer | Tests Kazal Pancreatic
      KOL-Index: 14641

      More than 1,000,000 men undergo prostate biopsy each year in the United States, most for "elevated" serum prostate-specific antigen (PSA). Given the lack of specificity and unclear mortality benefit of PSA testing, methods to individualize management of elevated PSA are needed. Greater than 50% of PSA-screened prostate cancers harbor fusions between the transmembrane protease, serine 2 (TMPRSS2) and v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG) genes. Here, we report a ...

      Known for Urine Tmprss2 | Prostate Cancer | Serum Psa | Erg Fusion | Erythroblastosis Virus
      KOL-Index: 14161

      Attempts to target mutant KRAS have been unsuccessful. Here, we report the identification of Smad ubiquitination regulatory factor 2 (SMURF2) and UBCH5 as a critical E3:E2 complex maintaining KRAS protein stability. Loss of SMURF2 either by small interfering RNA/short hairpin RNA (siRNA/shRNA) or by overexpression of a catalytically inactive mutant causes KRAS degradation, whereas overexpression of wild-type SMURF2 enhances KRAS stability. Importantly, mutant KRAS is more susceptible to ...

      Known for Protein Stability | Mutant Kras | Cancer Cells | Smurf2 Silencing | Proto Oncogene

      Key People For Prostate Cancer

      Top KOLs in the world
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Peter T Scardino
      prostate cancer active surveillance erectile function
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      Johnathan I Jonathan
      prostate cancer gleason score needle biopsy
      Philip W Kantoff
      prostate cancer psma adc androgen deprivation therapy
      prostate cancer specific antigen pathological stage

      Arul M Chinnaiyan:Expert Impact

      Concepts for whichArul M Chinnaiyanhas direct influence:Prostate cancer,  Gene fusions,  Gene expression,  Breast cancer,  Situ hybridization,  Prostate cancer progression,  Gene fusion,  Androgen receptor.

      Arul M Chinnaiyan:KOL impact

      Concepts related to the work of other authors for whichfor which Arul M Chinnaiyan has influence:Prostate cancer,  Gene expression,  Cell death,  Androgen receptor,  Hippo pathway,  Long noncoding rnas.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA | Department of Pathology, University of Michigan, Ann Arbor, MI, USA | Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA | Department of Pathology, University

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.